Back to Business

Jefferies reiterates Disc Medicine stock rating on polycythemia data

Business September 10, 2026 at 7:48 AM

Jefferies reiterates Disc Medicine stock rating on polycythemia data

Investing.com

Read at Investing.com

More Stories

Fever-Tree H1 shares fall as U.S. margin pressure offsets profit beat

Fever-Tree H1 shares fall as U.S. margin pressure offsets profit beat

🇺🇸 Investing.com 35m ago

European natural gas holds near multi-year peaks on supply risks; ECB decision due

European natural gas holds near multi-year peaks on supply risks; ECB decision due

🇺🇸 Investing.com 36m ago

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

🇺🇸 Investing.com 42m ago

Your world briefing, in your pocket

AI-curated news from 12 countries and 10 languages — coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play